June 24, 2015 | The Israeli medical aesthetics company PhotoMedex sold its XTRAC division for the treatment of vitiligo and psoriasis to Mela Sciences for $42.5 million. The acquisition will help PhotoMedex recover the debt from its acquisition of LCA opthalmological clinics. PhotoMedex is headquartered in Montgomeryville, Pennsylvania and is headed by CEO Dolev Rafaeli.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments